0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Psychiatry
Editorial  | 
Antipsychotic Use in Youth Without Psychosis A Double-edged Sword
Christoph U. Correll, MD; Joseph C. Blader, PhD
JAMA Psychiatry
Original Investigation  | 
Treatment of Young People With Antipsychotic Medications in the United States
Mark Olfson, MD, MPH; Marissa King, PhD; Michael Schoenbaum, PhD
JAMA Psychiatry
Original Investigation  | 
Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia A Prospective Dopamine D2/3 Receptor Occupancy Study
Ariel Graff-Guerrero, MD, PhD; Tarek K. Rajji, MD; Benoit H. Mulsant, MD, MS; et al.
JAMA Psychiatry
Editorial  | 
America’s Cannabis Experiment
David Goldman, MD